Novavax secures full US approval for COVID-19 vaccine
After a prolonged wait, American company Novavax (Nasdaq: NVAX) has received full approval from the US regulator for its protein-based COVID-19 vaccine, Nuvaxovid (COVID-19 vaccine, adjuvanted).
The Food and Drug Administration green light arrives more than six weeks after the original decision deadline, and the authorization is notably narrower than those granted to mRNA vaccines.
Nuvaxovid is now cleared for adults aged 65 and over, as well as those aged 12 to 64 who have at least one underlying health condition that increases their risk of severe COVID-19. This stands in contrast to the broader approvals for Moderna’s (Nasdaq: MRNA) Spikevax and Pfizer (NYSE: PFE) and BioNTech’s (Nasdaq: BNTX) Comirnaty, both of which are available to all individuals 12 and older, regardless of risk factors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze